Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Targeted hyperactivation of oncogenic STAT5-signaling in acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMark E. RobinsonJAJanis L. AbkowitzWAWarren S. Alexander

Discussion

Loading...

Member takes

Overview

Experimental treatment with STAT5-agonist ABBV-CLS-484 improves leukemia outcomes in acute lymphoblastic leukemia, suggesting autophagy roles.

Key Points

  • This research seeks to understand how targeted STAT5 signaling affects acute lymphoblastic leukemia outcomes.
  • Utilized gain- and loss-of-function models of STAT5 to assess effects on B-ALL cells.
  • Performed metabolomic analyses to identify changes in metabolic pathways under different STAT5 activities.
  • Examined the impact of drug treatments (imatinib, ruxolitinib, ABBV-CLS-484) on STAT5 activity and leukemia outcomes.
  • Higher STAT5 activity correlated with enhanced cell proliferation in acute lymphoblastic leukemia.
  • Inhibitors of JAK2 and BCR-ABL1 reduced acute lymphoblastic leukemia cell activity and increased quiescence.
  • Targeted hyperactivation with ABBV-CLS-484 prolonged survival in leukemia models.

Cite This Study

Robinson et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d062https://doi.org/10.1182/blood-2025-433
View Full Paper
Ask AI
Bookmark
Share